- $16.03m
- $14.23m
- $6.04m
- 96
- 44
- 65
- 77
Annual cashflow statement for PharmChem, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2001 December 31st | 2002 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | PRESS |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.48 | 3.34 | 1.85 | 0.87 | 0.723 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -0.382 | -4.35 | -0.123 | 0.116 | 0.075 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.23 | 0.091 | -0.687 | 0.143 | -0.189 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.61 | 1.34 | 0.875 | 1.27 | 0.639 |
| Capital Expenditures | -5.28 | -1.42 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.07 | 9.96 | 0.02 | 0 | — |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5.34 | 8.54 | 0.02 | 0 | — |
| Financing Cash Flow Items | 2.57 | -1.99 | — | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.26 | -5.87 | -6.51 | -0.2 | -2.35 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.175 | 4.02 | -5.62 | 1.07 | -1.71 |